

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT NEW EVIDENCE FOUND FOR EFFICACY OF SELF-OWNED AND DEVELOPED MEDICINE ISCHELIUM® ON BRAIN COGNITIVE FUNCTION IMPROVEMENT

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the recent developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that Dr. Liu Hongying, the chief medical officer of the Company, has led a team in the researches in collaboration with Chinese national key institutes of scientific research on the efficacy of a self-owned and developed medicine of the Group, Ischelium® (Dihydroergotoxine Methanesulfonate), on improving cognitive function. The latest research findings were accepted by “Biochemical and Biophysical Research Communications”, an international renowned academic journal.

Such fundamental research explored the intervention effect and potential mechanism of Ischelium® regarding declining cognitive function in an in-depth manner. As stated in the research, Ischelium® enhanced antioxidant enzyme activities in the hippocampus of laboratory animals, regulated Nrf2/HO-1 signaling pathway and reduced the production of pro-inflammatory cytokines IL-1 β and TNF- α in the hippocampus. This resulted in decreased expression of factors related to cognitive function, which in turn produced neuroprotective effects. Meanwhile, the research found that Ischelium® can significantly improve laboratory animals’ cognitive, learning and memory functions by protecting the neurons in the hippocampus. These findings have provided scientific basis for the potential of Ischelium® in slowing down aging, treating aging related diseases and improving the health of the elderly.

Information about Ischelium®

The Group's self-owned and developed medicine Ischelium® (Guoyaozhunzi (國藥准字) H20093234) has been approved in the PRC for years. Its mechanism of action is comprehensive and there is a wide range of potential target patients. With its extensive clinical applications, it has been widely recognized by clinical doctors in respect of mild vascular dementia and cerebrovascular disease. Ischelium® is an equal-proportion mixture of four dihydro derivatives of natural ergot alkaloids. The clinical research indicated that Ischelium® significantly improved the drooling symptom in patients with Parkinson's disease and it was recommended by "Consensus on the clinical management of gastrointestinal symptoms of patients with Parkinson's disease in China" in 2022, which further expanded the application of Ischelium® on aging related neurodegenerative disorder.

Cognitive impairment is considered to be the transitional phase between normal aging and Alzheimer's disease ("AD"). AD is an age related progressive neurodegenerative disorder with impaired cognitive function as its key clinical presentation. It may be caused by a combination of various factors such as genetic factors, environmental factors and bodily factors. This study provides further evidence that Ischelium® can significantly improve cognitive, learning and memory functions of aging animals and its potential mechanism of action, indicating its potential application regarding aging related diseases.

The Company has always been adhering to a patient-centered approach, focusing on digital chronic disease management, and at the same time, continuously exploring the frontiers of scientific research and service model innovation in chronic disease management, in order to contribute more to the health care of patients with chronic diseases. The Company has also initiated research on the prevention and treatment of AD and is looking forward to achieving more fruitful results in the future for the benefit of AD patients.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming

Chairman, Executive Director and Chief Executive Officer

Hong Kong, November 16, 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive director, Mr. Lee Kar Chung Felix as the non-executive director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive directors.

* *For identification purpose only*